Lantheus (LNTH) AI Stock Analysis

• Market Cap: $5.59B
• Dividend Yield: N/A
• Average Volume (3M): 1.00M
• Price to Earnings (P/E): 22.9
• Beta (1Y): 0.59
• Revenue Growth: 12.53%
• EPS Growth: -45.33%
• Country: US
• Employees: 808
• Sector: Healthcare
• Sector Strength: 46
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.53
• Shares Outstanding: 69,185,840
• 10 Day Avg. Volume: 961,514
• 30 Day Avg. Volume: 1,001,254
• PEG Ratio: -0.90
• Price to Book (P/B): 7.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.25
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 0.60
• Enterprise Value/Gross Profit: 3.69
• Enterprise Value/Ebitda: 1.62
• 1Y Price Target: $120.43
• Price Target Upside: 47.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 75 Outperform
• Price Target: $91.00 ▲(11.67%Upside)

Lantheus demonstrates a strong financial foundation and strategic growth opportunities through acquisitions. However, current technical indicators suggest a bearish trend, and the stock's valuation is moderate. The recent earnings call highlighted some challenges, including competitive pressures and revised guidance. These factors result in a balanced but cautious outlook for the stock.

Positive Factors

Radiopharmaceutical Opportunities

Lantheus Holdings is positioning itself to take advantage of the most promising medium- to long-term opportunities in the radiopharmaceutical field.

Revenue Growth Potential

Management continues to be excited about the prospect of returning to double-digit revenue growth anchored by flagship Pylarify and Definity with additional contributions from Neuraceq, Octevy, MK-6420, and PNT2003.

Strategic Partnerships and Expansion

Lantheus continues to secure strategic partnerships and plans to broaden contracting efforts and expand product availability.

Negative Factors

Blood-Based Diagnostics

The utility of blood-based diagnostics for Alzheimer’s disease could emerge as a headwind for Lantheus’s goal of introducing several beta amyloid- or tau-based PET tracers.

Competitive Pressure

PYLARIFY is facing competitive pressure and its net sales are down 0.5% year-over-year.

Financial Performance

Revenue came in below expectations, $257.7 million versus Street consensus of $265.1 million and analyst estimate of $262.8 million.

Lantheus Business Overview & Revenue Model

Company Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

How the Company Makes Money

Lantheus makes money by selling its diagnostic imaging agents and products to hospitals, clinics, and other healthcare providers. The company's revenue is primarily generated through the commercialization of its proprietary imaging agents, which are used to enhance the diagnostic capabilities of PET and SPECT imaging technologies. Lantheus also engages in strategic partnerships and collaborations with other pharmaceutical and biotechnology companies to expand its product offerings and reach in the market. Additionally, the company's revenue streams are supported by ongoing research and development efforts that lead to the introduction of new products and enhancements to existing ones, thereby sustaining and growing its market presence.

Lantheus Financial Statement Overview

Summary

Lantheus showcases a strong financial position across all verticals. The income statement reflects impressive growth and profitability, while the balance sheet indicates financial stability and efficient leverage management. The cash flow statement highlights robust cash generation and liquidity. The company's financial performance is characterized by healthy growth, strong margins, and efficient cash management, making it well-positioned in the drug manufacturing industry.

Income Statement

Lantheus exhibits impressive growth and profitability metrics. The TTM (Trailing-Twelve-Months) shows a robust gross profit margin of 64.05% and a strong net profit margin of 16.55%. Revenue growth has been exceptional, with significant increases year-over-year. The EBIT and EBITDA margins also reflect strong operational efficiency. Overall, the company demonstrates excellent revenue growth and healthy profitability in its income statement.

Balance Sheet

Lantheus maintains a solid balance sheet with a debt-to-equity ratio of 0.53, indicating moderate leverage. The company has a strong equity position, with an equity ratio of 56.65%, which signifies financial stability. Return on equity (ROE) is also impressive at 21.84%, highlighting effective use of equity to generate profits. The balance sheet reflects a healthy financial structure with a balanced approach to debt and equity.

Cash Flow

Lantheus demonstrates strong cash flow performance. The operating cash flow to net income ratio is 2.06, indicating efficient cash generation relative to net income. Free cash flow remains robust with a modest growth rate. The free cash flow to net income ratio of 1.86 suggests effective conversion of profits into cash. Overall, the company exhibits strong cash flow management and adequate liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.54B	1.53B	1.30B	935.06M	425.21M	339.41M
Gross Profit	984.14M	988.29M	709.54M	581.70M	187.69M	138.76M
EBITDA	438.66M	515.27M	491.00M	81.83M	-25.00M	22.69M
Net Income	254.32M	312.44M	326.66M	28.07M	-71.28M	-13.47M
Balance Sheet
Total Assets	2.06B	1.98B	1.65B	1.32B	863.78M	869.82M
Cash, Cash Equivalents and Short-Term Investments	938.53M	912.81M	713.66M	415.65M	98.51M	79.61M
Total Debt	614.40M	619.44M	616.95M	558.07M	174.76M	218.40M
Total Liabilities	891.03M	892.33M	835.26M	874.11M	399.35M	355.62M
Stockholders Equity	1.16B	1.09B	815.89M	447.15M	464.44M	514.21M
Cash Flow
Free Cash Flow	473.00M	493.13M	258.70M	263.43M	41.78M	3.92M
Operating Cash Flow	525.08M	544.75M	305.26M	281.78M	53.92M	16.40M
Investing Cash Flow	-183.20M	-226.01M	5.94M	-276.55M	3.68M	-4.91M
Financing Cash Flow	-119.91M	-118.54M	-13.06M	311.69M	-39.33M	-21.86M

Lantheus Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 81.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNTH, the sentiment is Neutral. The current price of 81.49 is above the 20-day moving average (MA) of 79.64, below the 50-day MA of 85.70, and below the 200-day MA of 94.06, indicating a neutral trend. The MACD of -0.73 indicates Negative momentum. The RSI at 51.77 is Neutral, neither overbought nor oversold. The STOCH value of 84.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LNTH.

Lantheus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RDY	77 Outperform	$12.69B	18.77	18.36%	0.62%	14.23%	-0.84%
LNTH	75 Outperform	$5.59B	22.91	24.11%	―	12.53%	-45.33%
NBIX	74 Outperform	$12.41B	42.53	12.43%	―	21.73%	-19.24%
Sector *	65 Neutral	¥345.58B	10.59	-2.88%	2.65%	11.80%	-7.09%
PRGO	63 Neutral	$3.65B	―	-3.64%	4.37%	-4.85%	-4290.31%
TEVA	62 Neutral	$19.73B	―	-18.98%	―	3.38%	-175.90%
VTRS	54 Neutral	$10.57B	―	-21.25%	5.26%	-6.88%	-6809.78%

Lantheus Corporate Events

Lantheus Completes Acquisition of Evergreen Theragnostics

On April 1, 2025, Lantheus Holdings, Inc. completed its acquisition of Evergreen Theragnostics, Inc., a move that enhances Lantheus’ capabilities across the radiopharmaceutical value chain. The acquisition, initially announced on January 28, 2025, includes Evergreen’s OCTEVY, a PET diagnostic imaging agent for neuroendocrine tumors, and a portfolio of theranostic pairs, as well as Evergreen’s radioligand therapy manufacturing infrastructure. This strategic acquisition positions Lantheus to better meet market demands and drive innovation, with potential milestone payments up to $727.5 million contingent on future achievements.